Related Experiment Video
Updated: Apr 5, 2026
Surgical Technique for the Implantation of Tissue Engineered Vascular Grafts and Subsequent In Vivo Monitoring
Published on: April 3, 2015
Direct bioresorbable vascular scaffold implantation: Feasibility and midterm results
Javier Suárez de Lezo1, Pedro Martín2, Francisco Mazuelos1
1Department of Cardiology, Reina Sofia Hospital, University of Córdoba (IMIBIC), Spain.
Objectives:
To analyze the feasibility and safety of direct bioresorbable vascular scaffold (BVS) implantation without previous balloon dilation.
Background:
Lesion preparation through predilation is recommended before BVS implantation. There is no information on the routine use of direct BVS implantation.
Methods And Results:
One hundred fifty-three patients with a total of 200 coronary lesions, were treated with BVS. A baseline intravascular ultrasound study (IVUS) was performed in 171 lesions (86%), and after BVS implantation, the quality of scaffolding was assessed with an additional IVUS (83, 41%) or optical coherence tomography (77, 38%). Elective predilation was conducted in 50 lesions. In 150 lesions, direct BVS implantation was attempted. In 129 lesions (86%), the BVS was implanted successfully, and in the remaining 21 (14%), direct implantation failed. In these cases, the scaffolds were retrieved and successfully implanted after balloon angioplasty. Longer and C-type lesions, and a larger plaque burden, were associated with failure to directly cross the lesion. Balloon postdilation was needed in 34% of the lesions. Ten patients (6.6%) had a periprocedural myocardial infarction. One patient (0.6%) died 60 days after BVS implantation due to thrombosis of the scaffold. At follow-up, target lesion revascularisation was needed in eight patients (5%). After 12 ± 3 months, the remaining patients were symptom-free.
Conclusions:
Direct BVS implantation is safe and feasible in most soft coronary plaques.
